Updates in the management of refractory colorectal cancer

In this week’s podcast, we bring you the latest developments in the field of refractory colorectal cancer. We are joined by Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain; Kathrin Heinrich, MD, Ludwig-Maximilians-Universität München, Munich, Germany; Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy; and Cristina Smolenski, MD, Gustave Roussy, Villejuif, France. We’ll hear about the current treatment landscape for refractory metastatic colorectal cancer, especially in the third-line settings, updates from the SOREGATT trial, which assessed regorafenib with chemotherapy in pretreated colorectal cancer, and the emerging role of fruquintinib, a selective VEGFR inhibitor, in patients who progress on regorafenib.